{"id":19894,"date":"2026-02-27T13:03:36","date_gmt":"2026-02-27T13:03:36","guid":{"rendered":"https:\/\/rayner.com\/us\/?p=19894"},"modified":"2026-02-27T15:53:02","modified_gmt":"2026-02-27T15:53:02","slug":"rayner-accelerates-momentum-in-the-us-with-strategic-anikavisc-deal","status":"publish","type":"post","link":"https:\/\/rayner.com\/us\/rayner-accelerates-momentum-in-the-us-with-strategic-anikavisc-deal\/","title":{"rendered":"Rayner accelerates momentum in the US with strategic Anikavisc\u00a0OVD\u00a0deal"},"content":{"rendered":"<p>Rayner today announced it has acquired the United States distribution rights to Anikavisc, the ophthalmic viscosurgical device (OVD), from Visco Technologies Inc &#8211; a move that strengthens the company\u2019s US cataract ecosystem and advances its mission to deliver a truly comprehensive portfolio of solutions.<\/p>\n<p>Anikavisc OVD is used intraoperatively to protect the corneal endothelium, maintain anterior chamber depth and enable controlled surgical manipulation. The cohesive formula is designed to deliver consistent performance and surgical efficiency.<\/p>\n<p>The acquisition comes at a pivotal moment for Rayner, as the company celebrates the US launch of its FDA-approved Sophi phaco platform and continues to expand access to its portfolio, including the RayOne EMV Toric IOL. With the PMA\u00a0for RayOne Galaxy \u2013 the world\u2019s first AI-designed spiral IOL \u2013 submitted, Rayner is positioning itself to offer a comprehensive, bundle-ready portfolio in 2026 \u2013 spanning premium and monofocal IOLs, OVD and advanced phaco technology.<\/p>\n<p>\u201cWe\u2019re excited about what this acquisition means for our US customers,\u201d said Scott Corning, Vice President Americas at Rayner. \u201cAnikavisc customers will see no changes to their current arrangements, but its reach and support will grow through our direct sales team from today. This also allows us to offer a fully bundled cataract solution, simplifying orders and streamlining purchasing, and delivers even greater value through one dedicated partner committed to innovation in cataract surgery.\u201d<\/p>\n<p>For more information, speak to your Rayner representative or visit <a href=\"http:\/\/www.rayner.com\">www.rayner.com<\/a>.<\/p>\n<p>&nbsp;<\/p>\n<p><strong>About Rayner:<\/strong><\/p>\n<p>Since the implantation of the first Rayner intraocular lens by Sir Harold Ridley in 1949, Rayner has had the goal to improve vision and restore sight worldwide. Today, Rayner\u2019s mission remains to deliver innovative and clinically superior ophthalmic products that respond to the expectations of our global customers to improve the sight and quality of life of their patients.<\/p>\n<p>Headquartered in Worthing, United Kingdom, Rayner markets its medical devices, pharmaceuticals, and digital solutions globally through a network of distributors and includes direct sales teams in the United Kingdom, Eire, USA, Canada, Brazil, India, Poland, Australia, Germany, Austria, Switzerland, France, Italy, Spain, and Portugal.<\/p>\n<p>Not all Rayner products are approved for sale in every country. Please contact your local Rayner distributor for details of which products are available in your area.<\/p>\n<p>\u00a92026 Rayner Group, all rights reserved. \u2018Rayner\u2019 \u2018RayOne\u2019 \u2018EMV\u2019 \u2018Sophi\u2019 and \u2018Galaxy\u2019 are proprietary marks of the Rayner Group. All other trademarks are property of their respective owners. Rayner, The Ridley Innovation Centre, 10 Dominion Way, Worthing, West Sussex, BN14 8AQ. Registered in England: 615539 | EC 2026-16 EN<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Rayner today announced it has acquired the United States distribution rights to Anikavisc, the ophthalmic viscosurgical device (OVD), from Visco Technologies Inc &#8211; a move that strengthens the company\u2019s US cataract ecosystem and advances its mission to deliver a truly comprehensive portfolio of solutions. Anikavisc OVD is used intraoperatively to protect the corneal endothelium, maintain<\/p>\n","protected":false},"author":368,"featured_media":19896,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[946,948],"tags":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Rayner accelerates momentum in the US with strategic Anikavisc\u00a0OVD\u00a0deal - Rayner : USA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/rayner.com\/us\/rayner-accelerates-momentum-in-the-us-with-strategic-anikavisc-ovd-deal\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rayner accelerates momentum in the US with strategic Anikavisc\u00a0OVD\u00a0deal - Rayner : USA\" \/>\n<meta property=\"og:description\" content=\"Rayner today announced it has acquired the United States distribution rights to Anikavisc, the ophthalmic viscosurgical device (OVD), from Visco Technologies Inc &#8211; a move that strengthens the company\u2019s US cataract ecosystem and advances its mission to deliver a truly comprehensive portfolio of solutions. Anikavisc OVD is used intraoperatively to protect the corneal endothelium, maintain\" \/>\n<meta property=\"og:url\" content=\"https:\/\/rayner.com\/us\/rayner-accelerates-momentum-in-the-us-with-strategic-anikavisc-ovd-deal\/\" \/>\n<meta property=\"og:site_name\" content=\"Rayner : USA\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-27T13:03:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-27T15:53:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/rayner.com\/us\/wp-content\/uploads\/sites\/5\/2026\/03\/RAY26052_Raynews-Header.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"khaldounkn@hotmail.com\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"khaldounkn@hotmail.com\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/rayner.com\/us\/rayner-accelerates-momentum-in-the-us-with-strategic-anikavisc-ovd-deal\/\",\"url\":\"https:\/\/rayner.com\/us\/rayner-accelerates-momentum-in-the-us-with-strategic-anikavisc-ovd-deal\/\",\"name\":\"Rayner accelerates momentum in the US with strategic Anikavisc\u00a0OVD\u00a0deal - Rayner : USA\",\"isPartOf\":{\"@id\":\"https:\/\/rayner.com\/us\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/rayner.com\/us\/rayner-accelerates-momentum-in-the-us-with-strategic-anikavisc-ovd-deal\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/rayner.com\/us\/rayner-accelerates-momentum-in-the-us-with-strategic-anikavisc-ovd-deal\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/rayner.com\/us\/wp-content\/uploads\/sites\/5\/2026\/02\/RAY26052_Raynews-Header.png\",\"datePublished\":\"2026-02-27T13:03:36+00:00\",\"dateModified\":\"2026-02-27T15:53:02+00:00\",\"author\":{\"@id\":\"https:\/\/rayner.com\/us\/#\/schema\/person\/50a1feada1baa8f6f03da458c72e76c5\"},\"breadcrumb\":{\"@id\":\"https:\/\/rayner.com\/us\/rayner-accelerates-momentum-in-the-us-with-strategic-anikavisc-ovd-deal\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/rayner.com\/us\/rayner-accelerates-momentum-in-the-us-with-strategic-anikavisc-ovd-deal\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/rayner.com\/us\/rayner-accelerates-momentum-in-the-us-with-strategic-anikavisc-ovd-deal\/#primaryimage\",\"url\":\"https:\/\/rayner.com\/us\/wp-content\/uploads\/sites\/5\/2026\/02\/RAY26052_Raynews-Header.png\",\"contentUrl\":\"https:\/\/rayner.com\/us\/wp-content\/uploads\/sites\/5\/2026\/02\/RAY26052_Raynews-Header.png\",\"width\":1920,\"height\":1080},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/rayner.com\/us\/rayner-accelerates-momentum-in-the-us-with-strategic-anikavisc-ovd-deal\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/rayner.com\/us\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rayner accelerates momentum in the US with strategic Anikavisc\u00a0OVD\u00a0deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/rayner.com\/us\/#website\",\"url\":\"https:\/\/rayner.com\/us\/\",\"name\":\"Rayner : USA\",\"description\":\"Rayner is a British manufacturer of ophthalmic medical products, including intraocular lenses (IOLs) and eye drops to support ocular health\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/rayner.com\/us\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/rayner.com\/us\/#\/schema\/person\/50a1feada1baa8f6f03da458c72e76c5\",\"name\":\"khaldounkn@hotmail.com\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/rayner.com\/us\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/c3b20c83acae48456e736c5af207c3c7?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/c3b20c83acae48456e736c5af207c3c7?s=96&d=mm&r=g\",\"caption\":\"khaldounkn@hotmail.com\"},\"url\":\"https:\/\/rayner.com\/us\/author\/khaldounknhotmail-com\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Rayner accelerates momentum in the US with strategic Anikavisc\u00a0OVD\u00a0deal - Rayner : USA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/rayner.com\/us\/rayner-accelerates-momentum-in-the-us-with-strategic-anikavisc-ovd-deal\/","og_locale":"en_GB","og_type":"article","og_title":"Rayner accelerates momentum in the US with strategic Anikavisc\u00a0OVD\u00a0deal - Rayner : USA","og_description":"Rayner today announced it has acquired the United States distribution rights to Anikavisc, the ophthalmic viscosurgical device (OVD), from Visco Technologies Inc &#8211; a move that strengthens the company\u2019s US cataract ecosystem and advances its mission to deliver a truly comprehensive portfolio of solutions. Anikavisc OVD is used intraoperatively to protect the corneal endothelium, maintain","og_url":"https:\/\/rayner.com\/us\/rayner-accelerates-momentum-in-the-us-with-strategic-anikavisc-ovd-deal\/","og_site_name":"Rayner : USA","article_published_time":"2026-02-27T13:03:36+00:00","article_modified_time":"2026-02-27T15:53:02+00:00","og_image":[{"width":1920,"height":1080,"url":"https:\/\/rayner.com\/us\/wp-content\/uploads\/sites\/5\/2026\/03\/RAY26052_Raynews-Header.png","type":"image\/png"}],"author":"khaldounkn@hotmail.com","twitter_card":"summary_large_image","twitter_misc":{"Written by":"khaldounkn@hotmail.com","Estimated reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/rayner.com\/us\/rayner-accelerates-momentum-in-the-us-with-strategic-anikavisc-ovd-deal\/","url":"https:\/\/rayner.com\/us\/rayner-accelerates-momentum-in-the-us-with-strategic-anikavisc-ovd-deal\/","name":"Rayner accelerates momentum in the US with strategic Anikavisc\u00a0OVD\u00a0deal - Rayner : USA","isPartOf":{"@id":"https:\/\/rayner.com\/us\/#website"},"primaryImageOfPage":{"@id":"https:\/\/rayner.com\/us\/rayner-accelerates-momentum-in-the-us-with-strategic-anikavisc-ovd-deal\/#primaryimage"},"image":{"@id":"https:\/\/rayner.com\/us\/rayner-accelerates-momentum-in-the-us-with-strategic-anikavisc-ovd-deal\/#primaryimage"},"thumbnailUrl":"https:\/\/rayner.com\/us\/wp-content\/uploads\/sites\/5\/2026\/02\/RAY26052_Raynews-Header.png","datePublished":"2026-02-27T13:03:36+00:00","dateModified":"2026-02-27T15:53:02+00:00","author":{"@id":"https:\/\/rayner.com\/us\/#\/schema\/person\/50a1feada1baa8f6f03da458c72e76c5"},"breadcrumb":{"@id":"https:\/\/rayner.com\/us\/rayner-accelerates-momentum-in-the-us-with-strategic-anikavisc-ovd-deal\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/rayner.com\/us\/rayner-accelerates-momentum-in-the-us-with-strategic-anikavisc-ovd-deal\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/rayner.com\/us\/rayner-accelerates-momentum-in-the-us-with-strategic-anikavisc-ovd-deal\/#primaryimage","url":"https:\/\/rayner.com\/us\/wp-content\/uploads\/sites\/5\/2026\/02\/RAY26052_Raynews-Header.png","contentUrl":"https:\/\/rayner.com\/us\/wp-content\/uploads\/sites\/5\/2026\/02\/RAY26052_Raynews-Header.png","width":1920,"height":1080},{"@type":"BreadcrumbList","@id":"https:\/\/rayner.com\/us\/rayner-accelerates-momentum-in-the-us-with-strategic-anikavisc-ovd-deal\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/rayner.com\/us\/"},{"@type":"ListItem","position":2,"name":"Rayner accelerates momentum in the US with strategic Anikavisc\u00a0OVD\u00a0deal"}]},{"@type":"WebSite","@id":"https:\/\/rayner.com\/us\/#website","url":"https:\/\/rayner.com\/us\/","name":"Rayner : USA","description":"Rayner is a British manufacturer of ophthalmic medical products, including intraocular lenses (IOLs) and eye drops to support ocular health","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/rayner.com\/us\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-GB"},{"@type":"Person","@id":"https:\/\/rayner.com\/us\/#\/schema\/person\/50a1feada1baa8f6f03da458c72e76c5","name":"khaldounkn@hotmail.com","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/rayner.com\/us\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/c3b20c83acae48456e736c5af207c3c7?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c3b20c83acae48456e736c5af207c3c7?s=96&d=mm&r=g","caption":"khaldounkn@hotmail.com"},"url":"https:\/\/rayner.com\/us\/author\/khaldounknhotmail-com\/"}]}},"_links":{"self":[{"href":"https:\/\/rayner.com\/us\/wp-json\/wp\/v2\/posts\/19894"}],"collection":[{"href":"https:\/\/rayner.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/rayner.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/rayner.com\/us\/wp-json\/wp\/v2\/users\/368"}],"replies":[{"embeddable":true,"href":"https:\/\/rayner.com\/us\/wp-json\/wp\/v2\/comments?post=19894"}],"version-history":[{"count":3,"href":"https:\/\/rayner.com\/us\/wp-json\/wp\/v2\/posts\/19894\/revisions"}],"predecessor-version":[{"id":19898,"href":"https:\/\/rayner.com\/us\/wp-json\/wp\/v2\/posts\/19894\/revisions\/19898"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/rayner.com\/us\/wp-json\/wp\/v2\/media\/19896"}],"wp:attachment":[{"href":"https:\/\/rayner.com\/us\/wp-json\/wp\/v2\/media?parent=19894"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/rayner.com\/us\/wp-json\/wp\/v2\/categories?post=19894"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/rayner.com\/us\/wp-json\/wp\/v2\/tags?post=19894"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}